



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Communications

Orario	ID	Title	Presenting Author
22/10/2021 10.05 - 11.05 Clinical HIV			
10.05 - 10.20		Redesigning pregnancy in PLWH 2021	Francesca Vichi, Firenze
10.20 - 10.30	227	OC 1 Coinfection with Hepatitis B Virus and/or Hepatitis C Virus is a risk factor for HIV virological rebound in course of antiretroviral therapy	Vincenzo Malagnino, Roma
10.32 - 10.42	273	OC 2 Transitions in frailty phenotype states and its association with frailty index: A multi-state Markov model study	Giovanni Guaraldi, Modena
10.44 - 10.54	83	OC 3 Intrapartum use of zidovudine in HIV pregnant women in Italy. Is it still being used in the era of U=U?	Lucia Taramasso, Genova
22/10/2021 10.05 - 11.05 Epidemiology / Social Sciences I			
10.05 - 10.15	231	OC 4 Long-term follow-up in a community-based PrEP cohort: controlled increase in risk exposure	Pietro Leone Giovanni Vinti, Milano
10.17 - 10.27	188	OC 5 Chemsex use in a HIV pre-exposure prophylaxis (PrEP) program based in Milan	Camilla Muccini, Milano
10.29 - 10.39	177	OC 6 Between loss to follow-up and persistence of risky sexual behaviors: how the COVID-19 pandemic impacted access to PrEP	Erica Bacca, Modena
10.41 - 10.51	254	OC 7 Impact of COVID pandemic on sexual habits and pre-exposure prophylaxis retention in care in a community-based service	Roberto Rossotti, Milano
10.53 - 11.03	192	OC 8 School-based sexuality education in Italy 2016-2020: a highly heterogeneous scenario	Alice Chinelli, Pisa
22/10/2021 11.10 - 12.10 Coinfections and Hepatitis			
11.10 - 11.25		New anti-HBV drugs: virological and immunological bases	Valentina Svicher, Roma
11.25 - 11.35	161	OC 9 Enrichment of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg secretion and alters its structural stability	Lorenzo Piermatteo, Roma
11.37 - 11.47	160	OC 10 HBcrAg strongly correlates with higher HDV replicative activity and with enhanced liver inflammation and damage: implications for HBcrAg as a biomarker of disease progression in the setting of HDV co-infection	Romina Salpini, Roma
11.49 - 11.59	197	OC 11 Endocrine pathways of non-alcoholic fatty liver disease in people living with HIV	Stefano Renzetti, Brescia
22/10/2021 12.15 - 13.15 Clinical HIV & Clinical Covid I			
12.15 - 12.30		Therapeutic approaches with monoclonal antibodies in HIV and SARS-CoV-2 infections	Anna Maria Cattelan, Padova
12.30 - 12.40	163	OC 12 Higher risk of MABs clinical failure associated to bamlanivimab/etesevimab exposure and to infection by SARS-CoV-2 P.1/Gamma variant of concern in a real life setting	Valentina Mazzotta, Roma
12.42 - 12.52	130	OC 13 Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection	Lucia Diella, Bari
12.54 - 13.04	128	OC 14 Real life use of monoclonal antibodies and their impact on SARS-CoV-2 clearance kinetics: a single centre experience	Maria Mazzitelli, Padova



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Communications

Orario	ID	Title	Presenting Author
22/10/2021 14.15 - 15.15 Epidemiology / Social Sciences II			
14.15 - 14.25	178	OC 15 Correlates of treatment and disease burden in PLWH in Italy	Antonella Cingolani, Roma
14.27 - 14.37	80	OC 16 The fourth "95" is at reach	Franco Maggiolo, Bergamo
14.39 - 14.49	157	OC 17 Narratives of HIV-positive patients in the DIAMANTE study	Luigi Reale, Milano
14.51 - 15.01	19	OC 18 A telephone-based multidimensional interview in elderly people living with HIV from the GEPO cohort	Micol Ferrara, Torino
22/10/2021 16.25 - 17.25 Antiretroviral Therapy I			
16.25 - 16.35	38	OC 19 Trajectories of CD4/CD8 ratio at 96 weeks after switch to dolutegravir-based dual therapies in a multicentre cohort of ART-experienced patients	Antonio Falletta, Genova
16.37 - 16.47	66	OC 20 Increasing Trend of Pretreatment Integrase Inhibitors Resistance in a Cohort of Antiretroviral Therapy-Naïve People Living with HIV	Camilla Muccini, Milano
16.49 - 16.59	139	OC 21 Role of genotypic testing results for predicting virological failure in persons living with HIV with HIV-RNA ≤50 copies/mL who require an ART switch	Maria Santoro, Roma
17.01 - 17.11	30	OC 22 Evaluation of virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based regimen in a real-life setting	Daniele Armenia, Roma
17.13 - 17.23	118	OC 23 Evaluation of total HIV-DNA and residual viremia in HIV-1 infected individuals enrolled on the Be-OnE study who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: results over 96 weeks	Maria Santoro, Roma
22/10/2021 16.25 - 17.25 Epidemiology / Social Sciences III			
16.25 - 16.40		Breastfeeding: the ultimate U=U's goal?	Maria Grazia Di Benedetto, Catania
16.40 - 16.50	75	OC 24 From u = u to breastfeeding of women with viro-suppressed HIV	Lorenza Di Marco, Modena
16.52 - 17.02	171	OC 25 Preferences in long acting agents for HIV treatment in women living with HIV: a cross-sectional evaluation among 6 Italian clinical centers	Antonella Cingolani, Roma
17.04 - 17.14	244	OC 26 HCV infection among women prisoners: a snapshot of the Italian ROSE network	Elena Rastrelli, Viterbo
22/10/2021 17.30 - 18.30 Clinical HIV & Clinical Covid II			
17.30 - 17.40	175	OC 27 Impact of home treatment with glucocorticoids on risk of in-hospital death in patients with COVID-19 pneumonia	Andrea Dessilani, Modena
17.42 - 17.52	228	OC 28 Treatment of COVID-19 severe pneumonia: do all patients benefit from adding tocilizumab to glucocorticoids? An open label non-randomized study	Sara Volpi, Modena
17.54 - 18.04	96	OC 29 SARS-CoV-2 viral decay in COVID-19 patients treated with monoclonal antibodies in relationship to viral variant	Luigi Coppola, Roma
18.06 - 18.16	82	OC 30 Effectiveness of COVID-19 vaccine in health care workers, Milan, Italy	Andrea Lombardi, Milano
18.18 - 18.28	88	OC 31 Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH	Eugenio Milano, Bari



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Communications

Orario	ID	Title	Presenting Author
23/10/2021 10.05 - 11.05 Clinical HIV & Clinical Covid III			
10.05 - 10.15	116	OC 32 T-Lymphocyte subset absolute counts assessed at baseline represent a useful tool to predict 30-days mortality in hospitalized SARS-CoV-2 infected patients	Andrea Di Lorenzo, Roma
10.17 - 10.27	235	OC 33 HIV and SARS-CoV-2 co-infection: protective role of IL-10 in HIV-positive young individuals	Claudia Vanetti, Milano
10.29 - 10.39	138	OC 34 Sequelae at 12 months after COVID-19 in hospitalized adults: a multicenter study	Giulia Viero, Milano
10.41 - 10.51	150	OC 35 Bloodstream infections in COVID-19 patients: first-wave versus second-wave comparison	Livia Tartaglione, Milano
10.53 - 11.03	126	OC 36 Impact of a pro-active Infectious Diseases Consultation for the Management of a Multidrug-resistant Organisms Outbreak in a COVID-19 Hospital: a Three-Months Quasi-Experimental Prospective Study	Davide Fiore Bavaro, Bari
23/10/2021 11.10 - 12.10 Immunopathogenesis I			
11.10 - 11.25		The age-dependent B-cell response to SARS-CoV-2 between innate and adaptive memory	Rita Carsetti, Roma
11.25 - 11.40		Pregnancy and Sars-Cov-2: a novel virus in a unique population	Mara Biasin, Milano
11.40 - 11.50	65	OC 37 SARS-CoV-2 plasmatic viremia and T-cell immune response in hospitalized COVID-19 patients	Roberta Rovito, Milano
11.52 - 12.02	136	OC 38 T-lymphocyte specific response to SARS-CoV-2 peptides is detectable in patients with multiple sclerosis under treatment with disease modifying therapies, despite absent or low-level anti-Spike antibody titers. Which are the possible clinical implications?	Marco Iannetta, Roma
23/10/2021 12.15 - 13.15 Comorbidities I			
12.15 - 12.30		Into the lung: is there a synergy between HIV and SARS-CoV2?	Antonio Di Biagio, Genova
12.30 - 12.40	59	OC 39 SARS-CoV-2 infection and COVID-19 disease in a large cohort of PLWHIV	Franco Maggiolo, Bergamo
12.42 - 12.52	70	OC 40 Meningococcus B Vaccination Effectiveness against Neisseria gonorrhoeae Infection in PLWH: a Case-control Study	Angelo Roberto Raccagni, Milano
12.54 - 13.04	61	OC 41 A Machine Learning-Based Model to Predict the 15-Year Risk for Cardiovascular Disease in a Cohort of People Living with HIV	Camilla Muccini, Milano
23/10/2021 12.15 - 13.15 Immunopathogenesis II			
12.15 - 12.25	156	OC 42 The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates the immunoregulatory/inflammatory signals	Veronica Bordoni, Rome
12.27 - 12.37	259	OC 43 Detection of SARS-CoV-2 RNA and evaluation of neurofilament light chain in cerebrospinal fluid and plasma of COVID-19 patients	Maria Anronella Zingaropoli, Roma
12.39 - 12.49	266	OC 44 MMP-9 and TIMP-1 as a potential disease biomarker in patients with COVID-19 pneumonia	Maria Anronella Zingaropoli, Roma
12.51 - 13.01	154	OC 45 An NF-kB/Jak/Stat signaling pathways is involved in APOBEC3A induction following CCL2 neutralization in primary human macrophages	Laura Fantuzzi, Roma
13.03 - 13.13	216	OC 46 Oral mucosal immunity in SARS-CoV-2 infected and/or vaccinated subjects	Micaela Garziano, Milano



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Communications

Orario	ID	Title	Presenting Author
23/10/2021 14.15 - 14.45 Antiretroviral Therapy II			
14.15 - 14.25	158	OC 47 Associations between weight changes and plasmatic pro-inflammatory cytokines in PLWH following ART initiation: data from the ICONA cohort	Francesca Bai, Milano
14.27 - 14.37	111	OC 48 Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bicitgravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in patient with stable viral suppression	Stefania Cicalini, Roma
23/10/2021 14.15 - 14.45 Comorbidities II			
14.15 - 14.25	129	OC 49 Viral dynamics in cerebrospinal fluid of patients with Progressive Multifocal Leukoencephalopathy	Marcella Negri, Milano
14.27 - 14.37	170	OC 50 Switching to INSTI offsets negative effects of weight gain on incidence of insulin resistance in people living with HIV	Jovana Milic, Modena
23/10/2021 14.15 - 14.45 Virology and Pharmacology I			
14.15 - 14.25	267	OC 51 Virological and Serological Characterization of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination	Francesca Colavita, Roma
14.27 - 14.37	7	OC 52 Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected	Anna Gidari, Perugia
23/10/2021 14.50 - 16.20 Antiretroviral Therapy III			
14.50 - 15.00	182	OC 53 Effectiveness of lamivudine + dolutegravir (3TC+DTG) in persons living with HIV (PLWH) starting their first antiretroviral treatment	Antonella d'Arminio Monforte, Milano
15.02 - 15.12	106	OC 54 Reasons for choosing a TAF-based 3DR instead of a DTG-based 2DR as ART switch strategy for virologically suppressed PLWH in Italy	Alessandra Vergori, Roma
15.14 - 15.24	48	OC 55 An Italian non-interventional retrospective and prospective study in HIV-positive adult outpatients treated with D/C/F/TAF: the DIAMANTE study	Diego Ripamonti, Bergamo
15.26 - 15.36	251	OC 56 Prevalence, characteristics and outcome of Heavily treated experienced (HTE) HIV-infected patients: data from the Italian ICONA Cohort	Sergio Lo Caputo, Foggia
15.38 - 15.48	284	OC 57 BIC/FTC/TAF is effective on PLWH with low CD4 counts: real-life data from the Icona cohort	Alessandro Tavelli, Milano
15.50 - 16.00	194	OC 58 ART switch for pro-active, re-active or cost-saving reasons: a real world evaluation of the determinants over the period 2017-2020 in the Veneto Region	Anna Maria Cattelan, Padova
16.02 - 16.12	201	OC 59 Switching to Emtricitabine/Tenofovir Alafenamide/Bicitgravir on metabolic and hepatic safety: preliminary data from Surveillance Cohort Long-term Toxicity Antiretrovirals/antivirals (SCOLTA) project	Nicola Squillace, Monza



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Communications

Orario	ID	Title	Presenting Author
23/10/2021 14.50 - 16.20 Virology and Pharmacology II			
14.50 - 15.05		An update on the pharmacological strategies in the treatment of viral infections	Stefano Bonora, Torino
15.05 - 15.20		Pharmacology as a tool for polypharmacy management in HIV	Cristina Gervasoni, Milano
15.20 - 15.30	144 OC 60	Evaluation of factors potentially associated with Low-level viremia in PLWH from the Italian ARCA cohort: a matched Case-Control Study	Francesca Lombardi, Roma
15.32 - 15.42	142 OC 61	Distribution of tenofovir plasma trough concentrations in PLWH treated with doravirine	Dario Cattaneo, Milano
15.44 - 15.54	189 OC 62	SNP-168 of the protein kinase and CD4 or CD8 dynamic in HIV-1 patients	Chiara Brombin, Milano
15.56 - 16.06	203 OC 63	Interpatient variability in the pharmacokinetics of the remdesivir and main metabolite GS-441524 in treated COVID-19 subjects	Massimo Tempestilli, Roma
16.08 - 16.18	23 OC 64	Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests on isolates with contextual undetectable HIV-1 plasma viral load performed for clinical routine	Daniele Armenia, Roma
23/10/2021 14.50 - 16.20 Epidemiology / Social Sciences IV			
14.50 - 15.00	250 OC 65	Interest in injecting Long-Acting agents by people living with HIV in Italy: a picture from the Icona Network	Alessandro Tavelli, Milano
15.02 - 15.12	54 OC 66	Milan Fast Track City: study on HIV prevalence in two different settings	Diletta Barbanotti, Milano
15.14 - 15.24	202 OC 67	Impact of COVID-19 on HIV testing and counselling services in Lazio Region	Nicoletta Orchi, Roma
15.26 - 15.36	187 OC 68	Estimation of the proportion of people living with HIV in ART and virally suppressed, using surveillance and cohort data. Italy, 2012-2019	Navarra Assunta, Roma
15.38 - 15.48	37 OC 69	Prevalence of HIV infection in the PIPSA project carried out in Luanda, Angola. Data analysis by sex and age group	Teresa Baldoni, Catania
15.50 - 16.00	27 OC 70	High prevalence of mental health disorders in HIV positive adolescents and youths: an observational study from 8 health services in Beira district, Mozambique	Francesco Di Gennaro, Bari
16.02 - 16.12	10 OC 71	High prevalence of asymptomatic Sars-Cov2 infection in the cohort of Liver Transplant Recipients at INMI Spallanzani	Ubaldo Visco Comandini, Roma